TY - JOUR
T1 - Drug discovery in advanced prostate cancer
T2 - Translating biology into therapy
AU - Yap, Timothy A.
AU - Smith, Alan D.
AU - Ferraldeschi, Roberta
AU - Al-Lazikani, Bissan
AU - Workman, Paul
AU - De Bono, Johann S.
N1 - Funding Information:
The Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is supported in part by a programme grant from Cancer Research UK. Support is also provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer Research) and the National Institute for Health Research Biomedical Research Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research).
Publisher Copyright:
© 2016 Macmillan Publishers Limited, part of Springer Nature.
PY - 2016/9/29
Y1 - 2016/9/29
N2 - Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.
AB - Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses considerable therapeutic challenges. Recent genetic and technological advances have provided insights into prostate cancer biology and have enabled the identification of novel drug targets and potent molecularly targeted therapeutics for this disease. In this article, we review recent advances in prostate cancer target identification for drug discovery and discuss their promise and associated challenges. We review the evolving therapeutic landscape of CRPC and discuss issues associated with precision medicine as well as challenges encountered with immunotherapy for this disease. Finally, we envision the future management of CRPC, highlighting the use of circulating biomarkers and modern clinical trial designs.
UR - http://www.scopus.com/inward/record.url?scp=84979256228&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979256228&partnerID=8YFLogxK
U2 - 10.1038/nrd.2016.120
DO - 10.1038/nrd.2016.120
M3 - Review article
C2 - 27444228
AN - SCOPUS:84979256228
SN - 1474-1776
VL - 15
SP - 699
EP - 718
JO - Nature Reviews Drug Discovery
JF - Nature Reviews Drug Discovery
IS - 10
ER -